Lina Fang

Dr. Lina Fang


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
FWFuqi Wang
Fuqi Wang
XZXu Zhao
Xu Zhao
XSXin Su
Xin Su
DSDanni Song
Danni Song
FZFengmao Zou
Fengmao Zou
LFLina Fang
Lina Fang
Isorhamnetin, a main flavonoid component from the water extract of Sophorae Flos (an unopened dry flower bud ofSophora japonica), ameliorates uric acid levels and renal function by inhibiting XOD activity in hyperuricemic mice.

9 October 2009 in Chromatographia
Verified
Journal Article
Closed access
PDF file
ZSZhen Song
Zhen Song
XCXiaohui Chen
Xiaohui Chen
DZDi Zhang
Di Zhang
Lei RenLei Ren
Lei Ren
LFLina Fang
Lina Fang
KBKaishun Bi
Kaishun Bi

12 November 2020 in Bioanalysis
Verified
Journal Article
Closed access
LFLina Fang
Lina Fang
CZChunling Zhou
Chunling Zhou
MJMeihua Jiang
Meihua Jiang
XLXiaoxin Li
Xiaoxin Li
TLTianzhu Liu
Tianzhu Liu
AHAiping He
Aiping He
Aim: GW788388 is a selective and orally active TGF-β1 receptor inhibitor that shows potent activity in renal fibrosis. We aimed to establish and validate a simple and sensitive ultra-performance LC...

28 February 2020 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
JWJingyun Wang
Jingyun Wang
MMMeng Ming
Meng Ming
LYLin Yu
Lin Yu
GCGuangliang Chen
Guangliang Chen
NHNan Hao
Nan Hao
LFLina Fang
Lina Fang

1 December 2019 in Journal of Chromatography B
Verified
Journal Article
Closed access
JQJianyuan Qu
Jianyuan Qu
CZChunling Zhou
Chunling Zhou
NHNan Hao
Nan Hao
GCGuangliang Chen
Guangliang Chen
SXShuyue Xia
Shuyue Xia
LFLina Fang
Lina Fang

16 December 2020 in Journal of Analytical Methods in Chemistry
Verified
Journal Article
Open access
PDF file
CZChunling Zhou
Chunling Zhou
XLXiaoxin Li
Xiaoxin Li
AHAiping He
Aiping He
TLTianzhu Liu
Tianzhu Liu
JTJinmiao Tian
Jinmiao Tian
LFLina Fang
Lina Fang
VS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in oncology. In the present study, we established and validated a simple and sensitive UPLC-MS/MS method for the determination of VS-5584 in plasma samples. VS-5584 was separated via an Acquity UPLC BEH C18 column, with a mobile phase composed of acetonitrile and 0.2% formic acid in water (40 : 60). The calibration curve displayed a good linearity in the range of 1.0–1000 ng/mL, with satisfactory accuracy (−13.6% < RE% < 8.8%) and precision (CV%, less than 9.2%). The validated method was then applied to a pharmacokinetic study in rats. After administration of 10 mg/kg, VS-5584 was absorbed quickly and reached a peak concentration of 473.2 ± 72.0 ng/mL after 20 min. The established method allows for the quantification of VS-5584 in rat plasma in detail and can be utilized to successfully describe the pharmacokinetic profile of VS-5584.